Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are very rare dermatologic disorders characterized by extensive detachment of the epidermis. Although some drugs, infectious agents, HLA genes, malignancy and connective tissue diseases are thought to play a role in the development of the disease, the pathogenesis has not been fully elucidated. Type IV hypersensitivity reactions are thought to be the underlying cause of these diseases. Inflammatory changes such as purulent erosion, ulcers and crusting can be seen in the gastrointestinal system, urinary tract and genital mucosa. Some immunologic biyomarkers like as HLA-B* 1502, Granulysin and CCL-27 are used in clinical diagnosis, prognosis, treatment, and personalized new drug development that could further explain the pathogenesis of SJS and TEN. This review focuses on the pathophysiology of the SJS and TEN and presents it in light of current data on this subject. We recommend further in vivo and in vitro studies to unravel the underlying immunological mechanisms to determine appropriate intervention strategies.
Author contributions
Ayca Kocaaga and Mustafa Kocaaga performed literature review and drafted the manuscript. Mustafa Kocaaga drafted the table. All authors read and approved the final manuscript.
Funding
There no funding is required.
Declaration of Competing Interest
The authors declare that there are no financial or other conflicts of interest.
| [1] |
R. Frantz, et al., Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management, Med. (Kaunas. ) 57 (9) (2021).
|
| [2] |
T. Harr, L.E. French, Toxic epidermal necrolysis and Stevens-Johnson syndrome, Orphanet J. Rare Dis. 5 (2010) 39.
|
| [3] |
L.K. Gupta, et al., Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: an Indian perspective, Indian J. Dermatol. Venereol. Leprol. 82 (6) (2016) 603-625.
|
| [4] |
S. Meledathu, et al., Management of Stevens-Johnson syndrome/toxic epidermal necrolysis: a case report and literature review, J. Drugs Dermatol. 22 (11) (2023) e24-e28.
|
| [5] |
A. Hasegawa, R. Abe, Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis, F1000Res 9 (2020).
|
| [6] |
H.C. Chang, et al., A review of the systemic treatment of stevens-johnson syndrome and toxic epidermal necrolysis, Biomedicines 10 (9) (2022).
|
| [7] |
H. Shah, et al., Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: diagnosis and management, Am. J. Clin. Dermatol. 25 (6) (2024) 891-908.
|
| [8] |
M. Ziemer, et al., Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature, Br. J. Dermatol. 166 (3) (2012) 575-600.
|
| [9] |
E.P. Borrelli, et al., Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System, Epilepsia 59 (12) (2018) 2318-2324.
|
| [10] |
M.T. Belver, et al., Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS), Allergol. Immunopathol. (Madr. 44 (1) (2016) 83-95.
|
| [11] |
I.T. Abulatan, et al., A compilation of drug etiologies of stevens-johnson syndrome and toxic epidermal necrolysis, Cureus 15 (11) (2023) e48728.
|
| [12] |
M. Mockenhaupt, et al., The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multi-national perspective, J. Rheuma 30 (10) (2003) 2234-2240.
|
| [13] |
T.K. Patel, et al., A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population, Indian J. Dermatol. Venereol. Leprol. 79 (3) (2013) 389-398.
|
| [14] |
M. Chambel, et al., Clinical Stevens-Johnson syndrome and rufinamide: a clinical case, Allergol. Immunopathol. (Madr. 41 (1) (2013) 68-69.
|
| [15] |
A. Oliveira, M. Sanches, M. Selores, Stevens-Johnson syndrome and toxic epidermal necrolysis, Acta Med Port. 24 (4) (2011) 995-1002.
|
| [16] |
A. Bulisani, et al., Síndrome de Stevens-Johnson e necrólise epidérmica tóxica em medicina intensiva, Rev. Bras. De. Ter. Intensiv. 18 (2006).
|
| [17] |
P. Deshpande, et al., Immunopharmacogenomics: mechanisms of HLA-associated drug reactions, Clin. Pharm. Ther. 110 (3) (2021) 607-615.
|
| [18] |
J. Yun, et al., Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA, Allergy 67 (11) (2012) 1338-1346.
|
| [19] |
D.A. Ostrov, et al., Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire, Proc. Natl. Acad. Sci. USA 109 (25) (2012) 9959-9964.
|
| [20] |
B. Yarzabek, et al., Variations in HLA-B cell surface expression, half-life and extracellular antigen receptivity, Elife (2018) 7.
|
| [21] |
K.A. Hogquist, S.C. Jameson, The self-obsession of T cells: how TCR signaling thresholds affect fate 'decisions' and effector function, Nat. Immunol. 15 (9) (2014) 815-823.
|
| [22] |
L. Deng, R.A. Mariuzza, Recognition of self-peptide-MHC complexes by autoimmune T-cell receptors, Trends Biochem Sci. 32 (11) (2007) 500-508.
|
| [23] |
O. Correia, et al., Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement, Arch. Dermatol. 129 (4) (1993) 466-468.
|
| [24] |
L. Le Cleach, et al., Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors, Clin. Exp. Immunol. 119 (1) (2000) 225-230.
|
| [25] |
R. Abe, Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis, J. Dermatol. 42 (1) (2015) 42-48.
|
| [26] |
A. Nassif, et al., Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells, J. Allergy Clin. Immunol. 114 (5) (2004) 1209-1215.
|
| [27] |
T.M. Ko, et al., Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome, J. Allergy Clin. Immunol. 128 (6) (2011) 1266-1276.e11.
|
| [28] |
Y. Yang, et al., Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis, Austral J. Dermatol. 58 (3) (2017) e61-e67.
|
| [29] |
D.M. Koelle, et al., Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus, J. Clin. Invest 110 (4) (2002) 537-548.
|
| [30] |
T. Fujiyama, et al., Increased frequencies of Th 17 cells in drug eruptions, J. Dermatol. Sci. 73 (1) (2014) 85-88.
|
| [31] |
J. Louten, K. Boniface, R. de Waal Malefyt, Development and function of TH17 cells in health and disease, J. Allergy Clin. Immunol. 123 (5) (2009) 1004-1011.
|
| [32] |
Y. Teraki, M. Kawabe, S. Izaki, Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis, J. Allergy Clin. Immunol. 131 (3) (2013) 907-909.
|
| [33] |
N. Gagliani, et al., Th 17 cells transdifferentiate into regulatory T cells during resolution of inflammation, Nature 523 (7559) (2015) 221-225.
|
| [34] |
C.C. Ang, Y.K. Tay, Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis, Int J. Dermatol. 50 (12) (2011) 1570-1578.
|
| [35] |
R. Takahashi, et al., Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome, J. Immunol. 182 (12) (2009) 8071-8079.
|
| [36] |
J. Murata, R. Abe, H. Shimizu, Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment, J. Allergy Clin. Immunol. 122 (5) (2008) 992-1000.
|
| [37] |
C.C. Lan, et al., Diagnostic role of soluble fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: a pilot study, Acta Derm. Venereol. 86 (3) (2006) 215-218.
|
| [38] |
K. Stur, F.M. Karlhofer, G. Stingl, Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas, J. Invest Dermatol. 127 (4) (2007) 802-807.
|
| [39] |
C.N. Yeh, et al., Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction, J. Invest Dermatol. 134 (11) (2014) 2768-2775.
|
| [40] |
K. Sayama, et al., Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes, J. Invest Dermatol. 103 (3) (1994) 330-334.
|
| [41] |
I. Viard, et al., Inhibition of toxic epidermal necrolysis by blockade of CD 95 with human intravenous immunoglobulin, Science 282 (5388) (1998) 490-493.
|
| [42] |
R. Abe, et al., Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand, Am. J. Pathol. 162 (5) (2003) 1515-1520.
|
| [43] |
M. Tohyama, K. Hashimoto,Immunological mechanisms of epidermal damage in toxic epidermal necrolysis, Curr. Opin. Allergy Clin. Immunol. 12 (4) (2012) 376-382.
|
| [44] |
J.P. Medema, et al., Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis, Eur. J. Immunol. 27 (12) (1997) 3492-3498.
|
| [45] |
L.E. French, J.T. Trent, F.A. Kerdel, Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding, Int Immunopharmacol. 6 (4) (2006) 543-549.
|
| [46] |
R. Abe, et al., Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome, Ann. Intern Med 151 (7) (2009) 514-515.
|
| [47] |
W.H. Chung, et al., Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis, Nat. Med 14 (12) (2008) 1343-1350.
|
| [48] |
B. Lowin, M.C. Peitsch, J. Tschopp, Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity, Curr. Top. Microbiol Immunol. 198 (1995) 1-24.
|
| [49] |
S.J. Posadas, et al., Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity, J. Allergy Clin. Immunol. 109 (1) (2002) 155-161.
|
| [50] |
A. Downey, et al., Toxic epidermal necrolysis: review of pathogenesis and management, J. Am. Acad. Dermatol. 66 (6) (2012) 995-1003.
|
| [51] |
A.A. Kaspar, et al., A distinct pathway of cell-mediated apoptosis initiated by granulysin, J. Immunol. 167 (1) (2001) 350-356.
|
| [52] |
A.M. Krensky, C. Clayberger, Biology and clinical relevance of granulysin, Tissue Antigens 73 (3) (2009) 193-198.
|
| [53] |
Y. Fujita, et al., Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal ne-crolysis, J. Am. Acad. Dermatol. 65 (1) (2011) 65-68.
|
| [54] |
N. Saito, et al., Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome, Br. J. Dermatol. 167 (2) (2012) 452-453.
|
| [55] |
L.H. Lim, S. Pervaiz, Annexin 1: the new face of an old molecule, Faseb J. 21 (4) (2007) 968-975.
|
| [56] |
N. Saito, et al., An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions, Sci. Transl. Med 6 (245) (2014) 245ra295.
|
| [57] |
S.D. Kim, et al., Functional expression of formyl peptide receptor family in human NK cells, J. Immunol. 183 (9) (2009) 5511-5517.
|
| [58] |
W.H. Chung, S.I. Hung, Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis, J. Dermatol. Sci. 66 (3) (2012) 190-196.
|
| [59] |
I. Viard-Leveugle, et al., TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis, J. Invest Dermatol. 133 (2) (2013) 489-498.
|
| [60] |
B. Tapia, et al., Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions, J. Allergy Clin. Immunol. 114 (2) (2004) 335-340.
|
| [61] |
E. Morel, et al., Expression of α-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions, Allergy 66 (3) (2011) 360-367.
|
| [62] |
M. Kinoshita, et al., Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis, Sci. Transl. Med 13 (600) (2021).
|
| [63] |
A. Hasegawa, R. Abe, Stevens-Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management, Chin. Med J. ( Engl. ) 137 (19) (2024) 2294-2307.
|
| [64] |
W.H. Chung, S.I. Hung, Y.T. Chen,Human leukocyte antigens and drug hypersensitivity, Curr. Opin. Allergy Clin. Immunol. 7 (4) (2007) 317-323.
|
| [65] |
W.H. Chung, et al., Medical genetics: a marker for Stevens-Johnson syndrome, Nature 428 (6982) (2004) 486.
|
| [66] |
C.B. Man, et al., Association between HLA-B* 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese, Epilepsia 48 (5) (2007) 1015-1018.
|
| [67] |
W. Tassaneeyakul, et al., Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population, Epilepsia 51 (5) (2010) 926-930.
|
| [68] |
C. Lonjou, et al., A marker for Stevens-Johnson syndrome …: ethnicity matters, Pharm. J. 6 (4) (2006) 265-268.
|
| [69] |
A. Alfirevic, et al., HLA-B locus in Caucasian patients with carbamazepine hypersensitivity, Pharmacogenomics 7 (6) (2006) 813-818.
|
| [70] |
N. Kaniwa, et al., HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics 9 (11) (2008) 1617-1622.
|
| [71] |
C. Lonjou, et al., A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs, Pharm. Genom. 18 (2) (2008) 99-107.
|
| [72] |
T. Ozeki, et al., Genome-wide association study identifies HLA-A* 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population, Hum. Mol. Genet 20 (5) (2011) 1034-1041.
|
| [73] |
S.I. Hung, et al., HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc. Natl. Acad. Sci. USA 102 (11) (2005) 4134-4139.
|
| [74] |
S. Mallal, et al., Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, Lancet 359 (9308) (2002) 727-732.
|
| [75] |
M. Saag, et al., High sensitivity of human leukocyte antigen-b* 5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients, Clin. Infect. Dis. 46 (7) (2008) 1111-1118.
|
| [76] |
J. O'Brien, et al. Overview of MicroRNA Biogenesis, Mechanisms of Actions and Circulation, Front Endocrinol. (Lausanne) 9 (2018) 402.
|
| [77] |
J.A. Makarova, et al., Intracellular and extracellular microRNA: An update on localization and biological role, Prog. Histochem Cytochem 51 (3-4) (2016) 33-49.
|
| [78] |
A. Ichihara, et al., Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions, J. Allergy Clin. Immunol. 133 (4) (2014) 1065-1074.
|
PDF
(678KB)
